Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL).

ABSTRACT:

Purpose of review

There have been significant advances in the treatment of relapsed/refractory chronic lymphocytic leukemia (CLL) over the past two decades. However, the intention of treatment remains control of the disease and delay of progression rather than a cure which remains largely elusive. Considering that CLL is mostly seen in older patients, there are multiple factors that play a role in the selection of CLL beyond the frontline treatment. Here, we review the concept of relapsed CLL, factors that predispose to relapse, and therapeutic options available to this patient population. We also review investigational therapies and provide a framework for selection of therapies in this setting.

Recent findings

Targeted therapies with continuous BTK inhibitors (BTKi) or fix

SUBMITTER: Odetola O 

PROVIDER: S-EPMC10242240 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature